Methyl aminolevulinate

Drug Profile

Methyl aminolevulinate

Alternative Names: 5-ALA methylester; 5-ALA-methylesther; Aminolevulinic acid methyl ester; MAL-PDT; Methyl 5 aminolevulinate; Methylaminolevulinate; Metvix; Metvix Natural Daylight Photodynamic Therapy - Galderma; Metvix NDL-PDT; Metvix PDT; Metvixia; P 1202; Visonac

Latest Information Update: 09 Oct 2015

Price : $50

At a glance

  • Originator Norwegian Radium Hospital; PhotoCure
  • Developer Galderma; Healthcare Logistics; Photocure
  • Class Amino acids; Antineoplastics; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Squamous cell cancer
  • Phase II Acne

Most Recent Events

  • 09 Apr 2015 The product is approved for Actinic keratosis and Basal cell cancer in Mexico and is in phase-II development for Acne in USA, Canadd and Europe
  • 01 Mar 2015 Galderma initiates enrolment in a phase III trial for Actinic keratosis in France (NCT02373371)
  • 12 Aug 2014 Galderma in collaboration with Charité - Universitätsmedizin Berlin terminates phase III trial in Squamous cell cancer and actinic keratosis in Germany (EudraCT2012-004111-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top